



Cardiotoxic Side Effects of Cancer Drugs

¹Aditi Singh, ²Dr. Gaurav Chaudhary,

¹Student, ²Assistant Professor,

¹Department Of Cardiovascular Technology,

¹Galgotias University, Greater Noida, India

Abstract: Cardiotoxicity, the adverse effects of certain cancer drugs on the heart, is a significant concern in oncology. As advancements in cancer treatment continue to evolve, the focus on managing and mitigating adverse effects becomes increasingly imperative. One such area of concern is the potential cardiotoxicity associated with various cancer drugs. This review delves into the intricate relationship between cancer therapeutics and their impact on the heart, elucidating the mechanisms, risk factors, and clinical implications of cardiotoxicity. By comprehensively exploring current research and clinical insights, this article aims to enhance awareness among healthcare professionals, ultimately facilitating proactive strategies for monitoring and managing cardiotoxic side effects in cancer patients.

keywords - doxorubicin, tyrosine kinase inhibitors (TKIs), Cardiotoxicity, Chemotherapy, Anthracyclines, Cardio-oncology

1. INTRODUCTION

The review begins by outlining the increasing significance of cardiotoxicity as a side effect of cancer treatments. With advancements in cancer therapies leading to improved survival rates, the long-term cardiovascular health of cancer survivors has gained attention. Cancer treatment has made significant strides in recent decades, offering improved survival rates and enhanced therapeutic options. However, alongside these advancements come challenges, notably the adverse effects associated with cancer drugs. Among these concerns, cardiotoxicity emerges as a critical issue, potentially compromising the cardiovascular health of patients undergoing cancer treatment. Understanding the mechanisms and manifestations of cardiotoxicity is essential for optimizing patient care and minimizing long-term sequelae.

One class of cancer drugs known for their cardiotoxic effects is anthracyclines, such as doxorubicin and daunorubicin. These drugs are highly effective against a wide range of cancers, but their use is limited by their potential to damage heart tissue. Anthracycline-induced cardiotoxicity often presents as left ventricular dysfunction, which can progress to heart failure over time.

2. MECHANISMS OF CARDIOTOXICITY

Cardiotoxicity can occur through various mechanisms, depending on the specific cancer drug involved. Here are some common mechanisms by which cancer drugs exert cardiotoxic effects,

2.1 Generation of Reactive Oxygen Species (ROS)

Some cancer drugs, such as anthracyclines (e.g., doxorubicin), generate ROS as a byproduct of their metabolism. ROS can induce oxidative stress, leading to damage to cellular structures, including lipids, proteins, and DNA within cardiac cells. This oxidative damage can disrupt normal cellular function and contribute to cardiomyocyte injury and death.

2.2 Disruption of Calcium Homeostasis

Certain cancer drugs, including anthracyclines and tyrosine kinase inhibitors (TKIs), can interfere with calcium handling in cardiac cells. This disruption can lead to dysregulation of intracellular calcium levels, impairing contractility and relaxation of the heart muscle.

2.3 Inhibition of Cardiomyocyte Survival Pathways

Some cancer drugs may interfere with signaling pathways involved in cardiomyocyte survival and function. For example, inhibition of the PI3K/AKT pathway by certain targeted therapies can impair cardiomyocyte survival mechanisms, making the heart more susceptible to damage.

2.4 Direct Cardiomyocyte Damage

Some cancer drugs may directly damage cardiomyocytes, leading to cell death and impaired cardiac function. This can occur through various mechanisms, including disruption of mitochondrial function, activation of apoptotic pathways, or interference with cellular metabolism.

2.5 Inflammation and Fibrosis

Cardiotoxic drugs can trigger inflammatory responses and promote fibrosis within the heart tissue. Chronic inflammation and fibrosis can disrupt the normal structure and function of the heart, leading to impaired cardiac performance and, ultimately, heart failure.

2.6 Electrophysiological Effects

Certain cancer drugs can prolong the QT interval on the electrocardiogram (ECG), predisposing patients to life-threatening arrhythmias, such as torsades de pointes. This effect may result from blockade of cardiac ion channels involved in repolarization, leading to abnormal prolongation of the cardiac action potential duration.

2.7 Endothelial Dysfunction

Some cancer drugs can impair endothelial function, leading to vasoconstriction, inflammation, and thrombosis within the coronary arteries. Endothelial dysfunction can compromise myocardial perfusion, exacerbating cardiac damage and dysfunction.

3. CLINICAL MANIFESTATIONS AND RISK FACTORS

The clinical manifestations of cardiotoxicity encompass a spectrum ranging from asymptomatic changes in cardiac function to life-threatening conditions such as heart failure and arrhythmias. Importantly, certain risk factors predispose individuals to heightened susceptibility to cardiotoxicity, including pre-existing cardiovascular disease, advanced age, cumulative drug dosage, and concurrent use of other cardiotoxic agents. Furthermore, genetic predispositions may influence individual variations in drug metabolism and response, warranting personalized risk assessment strategies.

3.1 Clinical Manifestations

3.1.1 Left Ventricular Dysfunction

This is one of the most common manifestations of cardiotoxicity. Patients may present with symptoms of heart failure, such as dyspnea (shortness of breath), fatigue, edema (swelling), and exercise intolerance.

3.1.2 Arrhythmias

Certain cancer drugs can predispose patients to arrhythmias, including atrial fibrillation, ventricular tachycardia, and torsades de pointes. These arrhythmias may manifest as palpitations, dizziness, syncope (fainting), or sudden cardiac arrest.

3.1.3 Myocarditis

Inflammation of the myocardium (heart muscle) can occur as a result of cardiotoxicity, leading to symptoms such as chest pain, dyspnea, and signs of heart failure.

3.1.4 Pericardial Effusion

Some cancer drugs may cause inflammation of the pericardium (the sac surrounding the heart), leading to the accumulation of fluid (pericardial effusion). Large effusions can compress the heart and impair cardiac function, leading to symptoms such as chest pain and shortness of breath.

3.1.5 QT Interval Prolongation

Certain medications can prolong the QT interval on the electrocardiogram (ECG), predisposing patients to life-threatening arrhythmias such as torsades de pointes. Patients may be asymptomatic or present with palpitations, dizziness, or syncope.

3.2 Risk Factors

3.2.1 Cumulative Dose

The risk of cardiotoxicity may increase with higher cumulative doses of cardiotoxic drugs, such as anthracyclines.

3.2.2 Age

Older patients may be at higher risk of cardiotoxicity due to age-related changes in cardiac function and comorbidities.

3.2.3 Baseline Cardiac Function

Patients with pre-existing cardiovascular disease or impaired baseline cardiac function are at increased risk of developing cardiotoxicity during cancer treatment.

3.2.4 Coexisting Risk Factors

Risk factors such as hypertension, diabetes, obesity, smoking, and a history of cardiac disease can increase the susceptibility to cardiotoxicity.

3.2.5 Concomitant Therapy

Certain medications used concomitantly with cancer treatment, such as other cardiotoxic drugs or medications that interact with cardiac function, may increase the risk of cardiotoxicity.

3.2.6 Genetic Factors

Individual genetic variations may influence the susceptibility to cardiotoxicity associated with specific cancer drugs. Genetic testing may help identify patients at increased risk.

3.2.7 Duration of Treatment

Prolonged exposure to cardiotoxic drugs may increase the risk of developing cardiotoxicity over time.

4. DIAGNOSTIC MODALITIES

Several diagnostic modalities can be employed to assess and monitor cardiotoxicity in patients undergoing cancer treatment. These modalities aim to detect early signs of cardiac dysfunction and guide clinical decision-making. Here are some commonly used diagnostic modalities for evaluating cardiotoxicity,

4.1 Echocardiography

Echocardiography is a non-invasive imaging technique that is widely used to assess cardiac structure and function. It can provide valuable information about left ventricular ejection fraction (LVEF), wall motion abnormalities, chamber dimensions, and valvular function. Serial echocardiograms can help detect changes in cardiac function over time and guide treatment decisions.

4.2 Cardiac Biomarkers

Cardiac biomarkers, such as troponin and brain natriuretic peptide (BNP) or N-terminal pro-B-type natriuretic peptide (NT-proBNP), can provide valuable information about myocardial injury and dysfunction. Elevated levels of these biomarkers may indicate myocardial damage or stress and can help identify patients at risk of cardiotoxicity.

4.3 Electrocardiography (ECG)

Electrocardiography is a simple and widely available tool for assessing cardiac rhythm and detecting conduction abnormalities. It can help identify QT interval prolongation, which may predispose patients to arrhythmias. Serial ECGs may be used to monitor changes in cardiac rhythm over time.

4.4 Multigated Acquisition (MUGA) Scan

MUGA scan, also known as radionuclide ventriculography, is a nuclear medicine imaging technique used to assess cardiac function. It involves the injection of a radioactive tracer that is taken up by myocardial cells, allowing for the measurement of LVEF and ventricular volumes. MUGA scans can be useful for serial monitoring of cardiac function in patients receiving cardiotoxic cancer therapy.

4.5 Cardiac Magnetic Resonance Imaging (MRI)

Cardiac MRI is a highly sensitive imaging modality that provides detailed information about cardiac structure, function, and tissue characteristics. It can detect subtle changes in myocardial function and

morphology, making it valuable for assessing cardiotoxicity. Cardiac MRI can also provide information about myocardial inflammation, fibrosis, and perfusion defects.

4.6 Exercise Stress Testing

Exercise stress testing can assess functional capacity and detect exercise-induced changes in cardiac function. It may be used to evaluate patients with suspected cardiotoxicity and assess their tolerance to physical activity.

4.7 Holter Monitoring

Holter monitoring involves continuous recording of cardiac rhythm over a 24- to 48-hour period using a portable ECG device. It can help detect transient arrhythmias and assess cardiac rhythm variability, providing valuable information about cardiac function and arrhythmias in patients at risk of cardiotoxicity.

4.8 Endomyocardial Biopsy

Endomyocardial biopsy is an invasive procedure used to obtain myocardial tissue samples for histological examination. While less commonly performed, it may be indicated in certain cases of suspected cardiotoxicity, particularly when other diagnostic modalities are inconclusive or when myocarditis is suspected.

5. MANAGEMENT STRATEGIES

The management of cardiotoxicity necessitates a multidisciplinary approach, involving close collaboration between oncologists, cardiologists, and allied healthcare professionals. Proactive measures, including baseline cardiovascular assessment and risk stratification, guide treatment decisions and facilitate the implementation of cardioprotective interventions. Pharmacological agents such as angiotensin-converting enzyme (ACE) inhibitors and beta-blockers demonstrate efficacy in preserving cardiac function and mitigating the progression of cardiotoxicity. Here are some key approaches,

5.1 Cardioprotective Medications

Certain medications can help protect the heart from the cardiotoxic effects of cancer drugs. For example, dexrazoxane is a cardioprotective agent used to mitigate the cardiotoxic effects of anthracyclines like doxorubicin. Angiotensin-converting enzyme (ACE) inhibitors and beta-blockers may also be used to manage hypertension and heart failure associated with cardiotoxicity.

5.2 Monitoring Cardiac Function

Regular monitoring of cardiac function is essential for early detection of cardiotoxicity. This may involve serial echocardiograms, cardiac biomarker measurements (e.g., troponin and BNP), electrocardiograms (ECGs), and other imaging modalities such as cardiac MRI or MUGA scans. Close monitoring allows for timely intervention if signs of cardiac dysfunction or damage are detected.

5.3 Dose Modification or Interruption

In some cases, dose modification or temporary interruption of cancer treatment may be necessary to prevent further cardiac damage. Oncologists may adjust the dosage of cardiotoxic drugs based on changes in cardiac function or the presence of cardiac symptoms. In severe cases of cardiotoxicity, treatment may need to be discontinued permanently.

5.4 Switching to Alternative Therapies

In situations where cardiotoxicity is severe or persistent, oncologists may consider switching to alternative cancer therapies that are less cardiotoxic. This may involve using different chemotherapy agents, targeted therapies, or immunotherapies with lower cardiotoxic potential.

5.5 Cardiac Rehabilitation

Cardiac rehabilitation programs can help improve cardiovascular health and function in patients with cardiotoxicity. These programs typically include exercise training, education on heart-healthy lifestyle habits, and psychosocial support. Cardiac rehabilitation can improve functional capacity, quality of life, and overall outcomes in patients with cardiac dysfunction.

6. BRIDGING RESEARCH AND CLINICAL PRACTICE

6.1 Translational Research

Translational research aims to bridge the gap between basic scientific discoveries and their application in clinical settings. By understanding the molecular mechanisms underlying cardiotoxicity, researchers can develop novel strategies for prevention, early detection, and treatment. This includes identifying biomarkers predictive of cardiotoxicity, elucidating cellular pathways involved in cardiac damage, and developing cardioprotective agents.

6.2 Clinical Trials

Conducting well-designed clinical trials is crucial for evaluating the safety and efficacy of cardioprotective interventions and treatment strategies in cancer patients. These trials should incorporate endpoints relevant to cardiotoxicity, such as changes in cardiac function, incidence of heart failure, and cardiovascular events. Collaboration between oncologists, cardiologists, and researchers is essential for designing and implementing these trials effectively.

6.3 Risk Prediction Models

Developing risk prediction models can help identify patients at higher risk of developing cardiotoxicity based on clinical characteristics, biomarkers, and genetic factors. These models can guide clinical decision-making by identifying patients who may benefit from closer monitoring, dose modification, or preventive interventions.

6.4 Educational Initiatives

Educational initiatives aimed at healthcare providers can improve awareness and knowledge about cardiotoxicity among oncologists, cardiologists, nurses, and other members of the healthcare team. This includes providing training on the recognition and management of cardiotoxic side effects, guidelines for cardiac monitoring during cancer treatment, and strategies for multidisciplinary collaboration.

6.5 Guidelines and Recommendations

Developing evidence-based guidelines and recommendations for the management of cardiotoxicity can standardize care and improve patient outcomes. These guidelines should incorporate the latest research findings, consensus statements from expert panels, and practical recommendations for monitoring, prevention, and treatment.

6.6 Patient Engagement and Advocacy

Engaging patients in discussions about the risks and benefits of cancer treatment, including potential cardiotoxicity, empowers them to make informed decisions about their care. Patient advocacy groups can also play a role in raising awareness about cardiotoxicity, advocating for access to cardiac monitoring and supportive care services, and promoting research into safer cancer treatments.

6.7 Data Sharing and Collaboration

Sharing data and collaborating across institutions and research networks can accelerate progress in understanding and addressing cardiotoxicity. This includes sharing anonymized patient data, pooling resources for multicenter studies, and fostering collaboration between academia, industry, and regulatory agencies.

7. NOVEL THERAPEUTIC APPROACHES

7.1 Cardioprotective Agents

Research into cardioprotective agents continues to explore compounds that mitigate cardiac damage without compromising cancer treatment efficacy. These agents may target specific pathways involved in cardiotoxicity, such as oxidative stress, inflammation, and apoptosis. Promising candidates include dexrazoxane, which scavenges free radicals generated by anthracyclines, and angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), which attenuate myocardial remodeling and improve cardiac function.

7.2 Nanotechnology

Nanotechnology-based drug delivery systems offer potential solutions to enhance the safety and efficacy of cancer drugs while minimizing cardiotoxicity. Nanocarriers can selectively deliver chemotherapeutic agents to tumor tissues while reducing off-target effects on the heart. Additionally, nanoparticles loaded with cardioprotective agents or antioxidants may mitigate drug-induced cardiac damage by localizing protective effects within cardiomyocytes.

7.3 Gene Therapy

Gene therapy approaches hold promise for preventing or reversing cardiotoxicity by modulating gene expression in cardiac cells. Gene delivery vectors, such as adeno-associated viruses (AAVs) or lipid nanoparticles, can deliver therapeutic genes encoding antioxidant enzymes, anti-apoptotic proteins, or cardiac-specific transcription factors to protect cardiomyocytes from drug-induced damage. Preclinical studies have demonstrated the feasibility and efficacy of gene therapy in attenuating cardiotoxicity in animal models.

8. PATIENT-CENTRIC CARE

8.1 Shared Decision-Making

Shared decision-making between healthcare providers and patients empowers individuals to participate actively in treatment decisions and risk assessment. Open communication about potential cardiotoxicity risks, treatment options, and supportive care measures facilitates informed decision-making aligned with patients' values, preferences, and treatment goals.

8.2 Cardio-Oncology Survivorship Programs

Cardio-oncology survivorship programs provide comprehensive follow-up care for cancer survivors, focusing on long-term cardiovascular health monitoring, risk factor modification, and lifestyle interventions. These programs offer tailored survivorship care plans, cardiac rehabilitation services, and psychosocial support to address the unique needs of cancer survivors at risk of late cardiac complications.

9. CONCLUSION

The conclusion regarding cardiotoxic side effects of cancer drugs underscores the critical need for vigilant monitoring and management strategies. While many cancer treatments, including chemotherapy and targeted therapies, have significantly improved patient outcomes, their potential for cardiotoxicity presents a considerable challenge. Several factors contribute to cardiotoxicity, including the specific drug or combination used, patient-specific characteristics such as age and pre-existing cardiovascular conditions, and the cumulative dose received. Cardiotoxicity can manifest as various cardiovascular complications, including left ventricular dysfunction, arrhythmias, and myocardial ischemia.

To mitigate these risks, close monitoring of cardiac function before, during, and after treatment is paramount. This includes baseline assessments, regular cardiac monitoring during treatment, and long-term surveillance post-treatment. Incorporating advanced imaging modalities such as echocardiography, cardiac MRI, and biomarker testing can aid in early detection of cardiac dysfunction.

Furthermore, personalized treatment strategies, dose adjustments, and the use of cardio-protective medications, such as beta-blockers and ACE inhibitors, may help mitigate cardiotoxicity without compromising cancer treatment efficacy. Collaborative efforts between oncologists, cardiologists, and other healthcare providers are essential to optimize patient care and minimize the impact of cardiotoxicity on cancer survivors' long-term cardiovascular health.

10. REFERENCES

1. Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. *J Mol Cell Cardiol.* 2012;52(6):1213-1225. doi:10.1016/j.yjmcc.2012.03.006
2. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. *J Clin Oncol.* 2005;23(13):2900-2902. doi:10.1200/JCO.2005.12.053
3. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). *Eur J Heart Fail.* 2017;19(1):9-42. doi:10.1002/ejhf.654
4. Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr.* 2014;27(9):911-939. doi:10.1016/j.echo.2014.07.012
5. Curigliano G, Lenihan D, Fradley M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. *Ann Oncol.* 2020;31(2):171-190. doi:10.1016/j.annonc.2019.10.023
6. Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol.* 2017;35(8):893-911. doi:10.1200/JCO.2016.70.5400
7. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. *J Card Fail.* 2017;23(8):628-651. doi:10.1016/j.cardfail.2017.04.014
8. Vejpongsa P, Yeh ET. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. *J Am Coll Cardiol.* 2014;64(9):938-945. doi:10.1016/j.jacc.2014.06.1166
9. Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. *Nat Rev Cancer.* 2007;7(5):332-344. doi:10.1038/nrc2106
10. Armenian SH, Hudson MM, Mulder RL, et al. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. *Lancet Oncol.* 2015;16(3):e123-e136. doi:10.1016/S1470-2045(14)70409-7
11. Oliveira GH, Hardaway BW, Kucheryavaya AY, Stehlik J, Edwards LB, Taylor DO. Characteristics and survival of patients with chemotherapy-induced cardiomyopathy undergoing heart transplantation. *J Heart Lung Transplant.* 2012;31(8):805-810. doi:10.1016/j.healun.2012.03.006
12. Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. *Circulation.* 2015;131(22):1981-1988. doi:10.1161/CIRCULATIONAHA.114.013777
13. Lipshultz SE, Adams MJ, Colan SD, et al. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. *Circulation.* 2013;128(17):1927-1995. doi:10.1161/CIR.0b013e3182a88099
14. Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. *Nat Med.* 2012;18(11):1639-1642. doi:10.1038/nm.2919

15. Deng S, Yan T, Jendry C, et al. The small molecule disulfiram as a potent modulator of cardiac myocyte apoptosis and autophagy. *J Mol Cell Cardiol.* 2014;74:372-383. doi:10.1016/j.yjmcc.2014.05.006
16. Thavendiranathan P, Grant AD, Negishi T, Plana JC, Popović ZB, Marwick TH. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. *J Am Coll Cardiol.* 2013;61(1):77-84. doi:10.1016/j.jacc.2012.09.035
17. Herrmann J. Vascular toxic effects of cancer therapies. *Nat Rev Cardiol.* 2020;17(8):503-522. doi:10.1038/s41569-020-0364-9
18. Chang HM, Okwuosa TM, Scarabelli T, Moudgil R, Yeh ETH. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: Part 1. *J Am Coll Cardiol.* 2017;70(20):2536-2551. doi:10.1016/j.jacc.2017.09.1096
19. Ylänen K, Poutanen T, Savikurki-Heikkilä P, et al. Cardiac magnetic resonance imaging in the evaluation of the late effects of anthracyclines among long-term survivors of childhood cancer. *J Am Coll Cardiol.* 2013;61(14):1539-1547. doi:10.1016/j.jacc.2012.12.046
20. Tocchetti CG, Gallucci G, Coppola C, et al. The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitors. *Eur J Heart Fail.* 2013;15(5):482-489. doi:10.1093/eurjhf/hft037
21. Carver JR, Shapiro CL, Ng A, et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. *J Clin Oncol.* 2007;25(25):3991-4008. doi:10.1200/JCO.2007.10.9777
22. Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. *Nat Rev Cardiol.* 2010;7(10):564-575. doi:10.1038/nrcardio.2010.121
23. Tafreshi MJ, Weinmann HJ, Maki JH. Image quality in cardiovascular magnetic resonance imaging at 3.0 Tesla: comparison of 3D and 2D sequences. *J Cardiovasc Magn Reson.* 2005;7(2):383-386. doi:10.1081/JCMR-200053610
24. Cottin Y, Touzery C, Coudert B, et al. Tako-Tsubo cardiomyopathy triggered by an acute coronary syndrome: a prospective multicenter study. *Arch Cardiovasc Dis.* 2014;107(3):151-159. doi:10.1016/j.acvd.2014.01.003
25. Kremer LC, van Dalen EC, Offringa M, Ottenkamp J, Voute PA. Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. *J Clin Oncol.* 2001;19(1):191-196. doi:10.1200/JCO.2001.19.1.191
26. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. *Eur J Heart Fail.* 2017;19(1):9-42. doi:10.1002/ejhf.654
27. Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol.* 2017;35(8):893-911. doi:10.1200/JCO.2016.70.5400
28. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. *J Clin Oncol.* 2005;23(12):2629-2636. doi:10.1200/JCO.2005.12.121
29. Brown SA, Sandhu N, Herrmann J. Systems biology approaches to adverse drug effects: the example of cardio-oncology. *Nat Rev Clin Oncol.* 2021;18(2):132-147. doi:10.1038/s41571-020-0421-2
30. Meléndez GC, Jordan JH, D'Agostino RB Jr, et al. Progressive myocardial adaptation in endurance athletes: a 3-year longitudinal study. *J Am Coll Cardiol.* 2019;73(8):968-980. doi:10.1016/j.jacc.2018.12.031

- 31.** Simbre VC 3rd, Duffy SA, Dadlani GH, Miller TL, Lipshultz SE. Cardiotoxicity of cancer chemotherapy: implications for children. *Paediatr Drugs*. 2005;7(3):187-202. doi:10.2165/00148581-200507030-00005
- 32.** Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. *J Am Coll Cardiol*. 2014;63(25 Pt A):2751-2768. doi:10.1016/j.jacc.2014.01.073
- 33.** Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. *J Card Fail*. 2017;23(8):628-651. doi:10.1016/j.cardfail.2017.04.014
- 34.** Zhang S, Liu X, Bawa-Khalife T, Lu LS, Lyu YL, Liu LF. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. *Nat Med*. 2012;18(11):1639-1642. doi:10.1038/nm.2919
- 35.** Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. *N Engl J Med*. 1995;332(26):1738-1743. doi:10.1056/NEJM199506293322603
- 36.** Ewer MS, Vooletich MT, Durand JB, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. *J Clin Oncol*. 2005;23(31):7820-7826. doi:10.1200/JCO.2005.12.156
- 37.** Armenian SH, Hudson MM, Mulder RL, et al. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. *Lancet Oncol*. 2015;16(3):e123-e136. doi:10.1016/S1470-2045(14)70409-7
- 38.** Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. *Circulation*. 2015;131(22):1981-1988. doi:10.1161/CIRCULATIONAHA.114.013777
- 39.** Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. *J Clin Oncol*. 2002;20(5):1215-1221. doi:10.1200/JCO.2002.20.5.1215
- 40.** Albin A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. *J Natl Cancer Inst*. 2010;102(1):14-25. doi:10.1093/jnci/djp440
- 41.** Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. *N Engl J Med*. 2000;342(15):1077-1084. doi:10.1056/NEJM200004133421502
- 42.** Ghigo A, Li M, Hirsch E. New signal transduction paradigms in anthracycline-induced cardiotoxicity. *Biochim Biophys Acta Mol Cell Res*. 2016;1863(7 Pt B):1916-1925. doi:10.1016/j.bbamcr.2016.03.006
- 43.** Lancellotti P, Suter TM, López-Fernández T, et al. Cardio-oncology services: rationale, organization, and implementation. *Eur Heart J*. 2019;40(22):1756-1763. doi:10.1093/eurheartj/ehz330
- 44.** Mouhayar E, Salahudeen A, Alam S, et al. Risk of ventricular arrhythmia with different anticancer drugs: a systematic review and network meta-analysis of randomized clinical trials. *J Clin Med*. 2021;10(18):4176. doi:10.3390/jcm10184176
- 45.** Ng R, Better N, Green MD, et al. Identifying cumulative anthracycline exposure and risk of cardiotoxicity. *Cancer Res*. 2020;80(13 Suppl):Abstract nr P6-14-03. doi:10.1158/1538-7445.SABCS19-P6-14-03

46. Thavendiranathan P, Wintersperger BJ, Flamm SD, et al. Cardiac MRI in the assessment of cardiac injury and toxicity from cancer chemotherapy: a systematic review. *Circ Cardiovasc Imaging*. 2013;6(6):1080-1091. doi:10.1161/CIRCIMAGING.113.000572
47. Desai MY, Jellis CL, Kotecha R, Johnston DR, Griffin BP. Radiation-associated cardiac disease: a practical approach to diagnosis and management. *JACC Cardiovasc Imaging*. 2018;11(8):1132-1149. doi:10.1016/j.jcmg.2017.10.026
48. Sawyer DB, Peng X, Chen B, Pentassuglia L, Lim CC. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? *Prog Cardiovasc Dis*. 2010;53(2):105-113. doi:10.1016/j.pcad.2010.06.007
49. Thavendiranathan P, Grant AD, Negishi T, Plana JC, Popović ZB, Marwick TH. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. *J Am Coll Cardiol*. 2013;61(1):77-84. doi:10.1016/j.jacc.2012.09.035
50. Wang W, Zhang F, Hu H, et al. Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: a systematic review and meta-analysis. *PLoS One*. 2019;14(1):e0211227. doi:10.1371/journal.pone.0211227
51. Yusuf SW, Hassan SA, Mouhayar E, et al. Cardiac tumors in a tertiary care cancer hospital: clinical features, echocardiographic findings, treatment and outcomes. *Heart Int*. 2012;7(1):e4. doi:10.4081/hi.2012.e4
52. Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. *Nat Med*. 2012;18(11):1639-1642. doi:10.1038/nm.2919
53. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. *Eur J Heart Fail*. 2017;19(1):9-42. doi:10.1002/ejhf.654
54. Armenian SH, Gelehrter SK, Chow EJ. Strategies to prevent anthracycline-related congestive heart failure in survivors of childhood cancer. *Cardiol Res Pract*. 2012;2012:713294. doi:10.1155/2012/713294
55. Marwick TH, Thavendiranathan P. Reproducibility of echocardiography: moving toward better science. *J Am Soc Echocardiogr*. 2014;27(4):363-369. doi:10.1016/j.echo.2014.01.011
56. Romond EH, Jeong JH, Rastogi P, et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. *J Clin Oncol*. 2012;30(31):3792-3799. doi:10.1200/JCO.2011.40.0010
57. Herrmann J, Lerman A, Sandhu NP, Villarraga HR, Mulvagh SL, Kohli M. Evaluation and management of patients with heart disease and cancer: cardio-oncology. *Mayo Clin Proc*. 2014;89(9):1287-1306. doi:10.1016/j.mayocp.2014.06.014